Table 2.
Pooled patient-level data on the efficacy of CD47-SIRPα inhibitors in clinical trials.
| Total | Anti-CD47 mAbs | Selective SIRPα blockers | p value | |
|---|---|---|---|---|
| Total (n) | 771 | 341 | 430 | |
| ORR (%) | 16.7 | 12.6 | 20.0 | 0.11 |
| DCR (%) | 42.8 | 32.6 | 50.9 | 0.19 |
| Hematologic cancer (n) | 363 | 124 | 239 | |
| ORR (%) | 25.3 | 29.8 | 23.0 | 0.48 |
| DCR (%) | 56.7 | 54.0 | 58.2 | 0.69 |
| Solid cancer (n) | 408 | 217 | 191 | |
| ORR (%) | 9.1 | 2.8 | 16.2 | 0.079 |
| DCR (%) | 30.4 | 20.3 | 41.9 | 0.058 |
| Monotherapy in solid cancer (n) | 201 | 116 | 85 | |
| ORR (%) | 2.0 | 2.6 | 1.2 | 0.51 |
| DCR (%) | 21.4 | 11.2 | 35.3 | 0.081 |
| Combination in solid cancer (n) | 207 | 101 | 106 | |
| ORR (%) | 15.9 | 3.0 | 28.3 | 0.01* |
| DCR (%) | 39.1 | 30.7 | 47.2 | 0.28 |
*p<0.05.
mAb, monoclonal antibody; ORR, objective response rate; DCR, disease control rate.